Retatrutide appears to be a new medication in the fight against obesity. This revolutionary drug, categorized as a dual GLP-1 and GIP receptor agonist, exhibits promising results in investigations. By boosting these receptors, Retatrutide controls cravings, {promotesinsulin secretion, and ultimately